As leaders in a wide range of fields such as single-cell biology, computer science, mathematics, pathology, imaging and physics, LifeTime members will focus on bringing individual expertise together to change healthcare by tracking and understanding human cells during disease.
LifeTime has successfully applied for a Coordination and Support Action (CSA) published by the EU Horizon 2020 Future and Emerging Technologies (FET) Flagship programme. The CSA is scheduled to start in May 2019 and will run for one year.
The LifeTime Vision
LifeTime’s unifying goal is to understand and treat human cells during disease. The consequent deeper understanding of the molecular principles that drive the progression between healthy and disease cell states will promote breakthroughs in modern medicine and the advancement of precision medicine.
In the long-term LifeTime technologies will inform the physician about the molecular history of a patient's tissues, their future, and the consequences of perturbations or medical treatments, leading to early diagnosis and effective interception of disease.
Three Technology pillars
LifeTime aims to revolutionise healthcare by developing and integrating several emerging, disruptive technologies:
- single-cell biology
- artificial intelligence
LifeTime technologies will track and decipher the activity of our genomes in individual cells as they progress through time (ageing or disease) – "LifeTime".
The initiative is supported by more than 60 companies and by major European research organisations such as:
- Helmholtz Association in Germany
- National Centre for Scientific Research (CNRS) and INSERM in France
- Wellcome Trust in the United Kingdom
- Netherlands Organisation for Scientific Research (NWO)
- EU-LIFE Alliance
- national science academies
Header image by Spencer Phillips / EMBL-EBI